Fundació irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
J Clin Virol. 2013 Dec;58(4):726-9. doi: 10.1016/j.jcv.2013.09.022. Epub 2013 Oct 3.
The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors.
We aimed here to investigate whether this substitution pre-existed in treatment naive HCV/HIV-1 coinfected patients.
NS5B polymerase deep sequencing was performed at a median coverage per base of 4471 in 16 patient samples.
No S282T variant was detected in the 16 analyzed samples.
This finding is in agreement with the high genetic barrier of nucleoside analogues NS5B polymerase inhibitors and the clinical efficacy of these compounds.
S282T 突变是与耐核苷(酸)类似物丙型肝炎病毒(HCV)NS5B 聚合酶抑制剂相关的主要变异。
本研究旨在探讨该替代物是否预先存在于未经治疗的 HCV/HIV-1 合并感染患者中。
对 16 例患者样本进行 NS5B 聚合酶深度测序,每个碱基的中位覆盖率为 4471。
在分析的 16 个样本中均未检测到 S282T 变异。
这一发现与核苷类似物 NS5B 聚合酶抑制剂的高遗传屏障和这些化合物的临床疗效一致。